According to the latest study on ‘Liquid Biopsy Market Forecast to 2027 – Covid-19 Impact and Global Analysis by Product & Services, Sample, Circulating Biomarker, Application, and End User.’ The global liquid biopsy market was valued at US$ 3,861.49 million in 2019 and is projected to reach US$ 8,123.85 million by 2027; it is expected to grow with a CAGR of 9.9% during 2020–2027.The report provides trends prevailing in the global liquid biopsy market and the factors driving market along with those that act as hindrances.
Based on product & services, the liquid biopsy market is segmented into equipment, reagents & kits and services. The reagents & kits segment held the largest share of the market in 2019 and the same segment is anticipated to register the highest CAGR of 10.3% in the market during the forecast period. The growth of reagents & kit segment is attributed to the enhancement of solution to improve staining results and unique antibodies with fluorescent staining markers. There are various reagent & kits available in market for the detection of cancerous cell. For instance, MagMAX cell-free total nucleic acid isolation kit used to isolate and purify cfRNA and cfDNA from serum, plasma, or urine samples with the help of magnetic bead-based technology.
- Biocept, Inc
- Bio-Rad Laboratories Inc
- LungLife AI, Inc
- Exosome Diagnostics
- F. Hoffmann-la Roche ltd
- Exact Sciences Corporation
- Inivata Ltd
- Thermo Fisher Scientific Inc
Request For Sample Reports @ https://www.theinsightpartners.com/sample/TIPRE00003996/
The increasing prevalence of cancer is the major factor driving the growth of the market. However, low sensitivity of liquid biopsy is likely to restrain the growth of the market during the forecast years.
Biocept, inc., Bio-Rad Laboratories, Inc., Lunglifeai, inc, Exosome Diagnostics, F. Hoffmann-la Roche ltd, Inivata ltd,Exact sciences corporation, Mdxhealth, Qiagen, and Thermo fisher scientific inc. are among the key players present in the liquid biopsy market. The companies are focused on following organic strategies such as product launches and business expansions to sustain their position in the dynamic market. For instance, in November 2019, Thermo Fisher Scientific launched a product namely Oncomine Precision Assay, which is innovative pan-cancer panel for the Genexus platform. It is likely to perform, genomic profiling from formalin-fixed, paraffin-embedded (FFPE) tissue and liquid biopsy samples with a single assay.
Product launches and approval strategies are commonly adopted by companies to expand their footprint worldwide and meet the growing demand.
The market players operating in the liquid biopsy market adopt the business expansion to enlarge customer base across the world, collaborations, and product launches. These strategies permit the players to maintain their brand name globally. For instance, in August 2018, Exact Sciences Corp. announced signing of partnership with Pfizer to promote Colorguard in the US. Pfizer has helped with sales representative to promote the test to physicians and health systems during marketing campaign.
Liquid Biopsy Market – By Product & Service
- Reagents & Kits
Liquid Biopsy Market – By Sample
- Blood Based
- Urine Based
- Other samples
Liquid Biopsy Market – By Circulating Biomarker
- Circulating Tumor Cells (CTC)
- Free Nucleic Acid
Liquid Biopsy Market – By Application
- Noninvasive Prenatal Testing (NIPT)
- Transplant Diagnostics
- Other Applications
Liquid Biopsy Market – By End User
- Academic & Research Institutes
- Reference Laboratories
- Other End Users
Liquid Biopsy Market – By Geography
- North America
- Rest of Europe
- Asia Pacific (APAC)
- South Korea
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of Middle East and Africa
- South America
- Rest of South America
You Can Buy This Report from Here@ https://www.theinsightpartners.com/buy/TIPRE00003996/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.